arrow
J

Jad Othman

Royal Northshore Hospital
H指数:15
被引数:911

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia

ELN-DAVID 关于急性髓系白血病患者基于NGS的FLT3-ITD微小残留病检测的建议

Blood
IF23.1
2026-06-050
OAAI
Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients

TNF及其靶点的升高水平是风险较低的老年急性髓系白血病患者的特征

Leukemia
IF13.4
2026-04-010
OAAI
A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years

一项结合米哚妥林、低剂量阿糖胞苷和维奈克拉的新诊断AML(≥60岁)患者的随机Ⅱ期研究

Blood
IF23.1
2026-01-010
PRE
Measurable residual disease detection in acute lymphoblastic leukaemia: comparison between targeted next-generation sequencing and allele-specific oligonucleotide real-time quantitative polymerase chain reaction

急性淋巴细胞白血病的可测量残留病灶检测:靶向下一代测序与等位基因特异性寡核苷酸实时定量聚合酶链反应的比较

2025-11-250
PRE
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Gilteritinib在二线治疗后的有效性:一项关于171例复发/难治性FLT3突变急性髓系白血病患者的真实世界多中心研究

2025-11-010
OAAI
Safety and Efficacy of Combining Midostaurin and Gemtuzumab Ozogamicin with Induction Chemotherapy in FLT3 mutated AML.

联合中剂量阿糖胞苷和吉妥单抗奥佐米星与诱导化疗在FLT3突变急性髓系白血病中的安全性和有效性。

2025-10-030
OAAI
Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival

急性髓系白血病细胞表达高水平的雄激素受体,但不依赖雄激素信号存活。

Leukemia
IF13.4
2025-09-110
OAAI
A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1mut AML in MRDneg remission after intensive induction

对3项大型多中心试验的合并分析证实,在强化诱导后,NPM1mut AML在MRDneg缓解期具有生存优势。

2025-08-220
OAAI
Induction chemotherapy and molecular MRD influence outcomes in KMT2A rearranged AML

诱导化疗和分子MRD影响KMT2A重排AML的结局

Blood
IF23.1
2025-08-080
PRE
GFI1B is a metabolic regulator that exerts pleiotropic effects on platelet function

GFI1B是一种代谢调节因子,对血小板功能具有多效性影响。

2025-07-010
PRE
A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax plus /- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

一项比较低剂量阿糖胞苷和维奈克拉联合/不联合米哚妥林治疗非不良染色体风险急性髓系白血病的II期随机试验:ALLG AMLM25干预试验

BLOOD
IF23.1
2024-11-050
PRE
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
2024-10-250
OAAI
Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from Australia and New Zealand Transplant and Cellular Therapies
2024-03-011
PRE
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
2023-08-1114
OAAI
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
LEUKEMIA
IF13.4
2023-08-0920
OAAI